Communiqués Antengene Corporation Limited

Actions

6996

KYG039571008

Recherche biotechnologique et médicale

Temps Différé Hong Kong S.E. 05:51:08 14/09/2026			Varia. 5j.	Varia. 1 janv.
3,335 ^HKD	-0,15%		-4,71%	-12,01%

25/08	Antengene Corporation Limited reçoit l'approbation du HREC en Australie pour l'étude de phase I ATTRACT sur l'ATG-201 dans les maladies auto-immunes liées aux lymphocytes B	CI
25/08	Antengene : feu vert en Australie pour un essai de phase I sur un candidat-médicament contre les maladies auto-immunes	MT

Communiqués

06:28	Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy	PR
25/08	Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases	PR
24/08	Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D	PR
19/08	Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit	PR
20/07	Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026	PR
13/07	Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB	PR
22/06	Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE	PR
10/06	Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China	PR
08/06	Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance	PR
03/06	Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026	PR
28/05	Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer	PR
20/05	Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline	PR
18/04	Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs	PR
20/03	Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability	PR
18/03	Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs	PR
02/03	XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication	PR
25/02	Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)	PR
16/01	Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs	PR
17/12	Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma	PR
02/12	Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy	PR
20/11	Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs	PR
27/10/25	Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025	PR
20/10/25	Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability	PR
19/09/25	Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025	PR
22/08/25	Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform	PR